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INTRODUCTION
•  Immunotherapies have become revolutionary treatment 
modalities for several malignancies including patients with 
advanced melanoma and non-small cell lung carcinoma.
•  New immunotherapy treatments can result in unique 
adverse events due to increased inflammation in any 
organ in the body. Common immune-related adverse 
events include vitiligo, colitis, hepatitis, pneumonitis, and 
endocrinopathies, most commonly thyroiditis. 
CASE PRESENTATION
•  A 77-year-old male with metastatic choroidal melanoma 
treated with 2 cycles of Ipilimumab and Nivolumab 
presented to the hospital with complaints of generalized 
weakness, malaise, loss of appetite and 20 lb. weight 
loss over a two-week period. 
•  His concerns were initially attributed to progression of his 
known malignancy, however he developed further 
symptoms of intermittent fevers with eosinophilic 
leukocytosis, hypotension, disorientation, lethargy, 
tremors, incoherent speech, and urinary incontinence. 
•  Further work-up with MRI brain showed no new 
metastases or abnormalities and EEG was without 
epileptic foci. Infectious workup was unrevealing except 
for a questionable right lower lobe infiltrate on chest 
x-ray, which was subsequently treated with antibiotics. 
CT chest/abdomen/pelvis showed pulmonary 
metastases without further abnormalities. 
•  With symptoms concerning for possible adrenal insuffi-
ciency, a random cortisol was checked resulting at 1.7 
ug/dL. Adrenocorticotropic hormone (ACTH) stimulation 
test confirmed the diagnosis of adrenal insufficiency  
with the highest resultant level of 9.3 ug/dL. A low  
ACTH level of <5 confirmed the diagnosis of secondary 
adrenal  insufficiency.
•  Treatment was initiated with methylprednisolone 60mg 
 intravenously every 12 hours with concern for auto-
immune hypophysitis related to immunotherapy. 
 Symptoms began improving rapidly with steroid initiation. 
•  Further Endocrine evaluation revealed mild TSH elevation 
but otherwise normal FSH, LH, Prolactin, and insulin 
growth factor-1. 
DISCUSSION
•  This case uniquely exhibits immunotherapy induced 
 isolated ACTH deficiency, rather than hypophysitis. 
 Hypo physitis can occur with an adverse event rate up  
to 17% while on Ipilimumab, however isolated ACTH 
 deficiency is rarer. 
•  Diagnosis is challenging with symptomatology mimicking 
common malignancy complaints. It is important for all 
physicians to be able to recognize symptoms of secondary 
adrenal insufficiency, especially as a side effect of immu-
notherapy, as this condition is life threatening and requires 
immediate diagnosis and treatment. 
